Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immunovant, Inc.IMVT · Entity 3632 | Director | August 28, 2026 | August 28, 2026 |
| Sio Gene Therapies Inc.SIOX · Entity 130622 | Director | April 15, 2021 | April 19, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immunovant, Inc.
Report date August 28, 2026 · Filed August 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 116,731 |
Ending reported balance
After 2026-08-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-28 · Exercise / conversion · Acquired 1,500 · Balance 118,231 F1: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025. Row 2 · 2026-08-28 · Sale · Disposed 1,500 · Balance 116,731 F1: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.43 · Expires 2029-11-19 | Direct | 65,181 |
Reported balance
After 2026-08-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-28 · Exercise / conversion · Disposed 1,500 · Balance 65,181 F1: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025. F2: Reflects an award of stock options to purchase Common Shares that is fully vested. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 20,000 |
Reported balance
Holding disclosure · report date 2026-08-28 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 20,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025.
F2: Reflects an award of stock options to purchase Common Shares that is fully vested.
Sio Gene Therapies Inc.
Report date April 15, 2021 · Filed April 19, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.47 · Expires 2031-04-14 | Direct | 42,000 |
Reported balance
After 2021-04-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-04-15 · Grant · Acquired 42,000 · Balance 42,000 F1: 100% of this option will vest on April 15, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested shares of common stock. All shares of common stock underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of this option will vest on April 15, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested shares of common stock. All shares of common stock underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Karuna Therapeutics, Inc.
Report date March 18, 2024 · Filed March 18, 2024
Section 16 reporting ended · disclosed 2024-03-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 1
1 source rowRow 1 · 2024-03-18 · Disposition to issuer · Disposed 990 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F2: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $97.59 · Expires 2030-06-04 | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-03-18 · Disposition to issuer · Disposed 12,500 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F4: These Options are fully vested. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $128.01 · Expires 2031-06-15 | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-18 · Disposition to issuer · Disposed 8,500 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F4: These Options are fully vested. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $102.96 · Expires 2032-06-14 | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-03-18 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F4: These Options are fully vested. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $237.70 · Expires 2033-06-19 | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-03-18 · Disposition to issuer · Disposed 1,904 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F5: These Options originally provided for vesting upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax.
F2: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration.
F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option.
F4: These Options are fully vested.
F5: These Options originally provided for vesting upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 01, 2021 Filed Nov 3, 2021 20:14 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 2,500 | $136.67 | $341,675.00 |
DisclosureSEC source: 0001593968-21-002355 · primary_01.xml · nonDerivative · entry 2 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2021. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 20:14 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionCommon Stock | 2,500 | $16.00 | $40,000.00 |
DisclosureSEC source: 0001593968-21-002355 · primary_01.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2021 Filed Oct 1, 2021 20:21 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionOption (right to buy) · Derivative | 2,500 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001593968-21-002217 · primary_01.xml · derivative · entry 3 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 2,500 shares Expires 2029-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2021 Filed Oct 1, 2021 20:21 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 2,500 | $120.72 | $301,800.00 |
DisclosureSEC source: 0001593968-21-002217 · primary_01.xml · nonDerivative · entry 2 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2021. Read SEC document |
| October 01, 2021 Filed Oct 1, 2021 20:21 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionCommon Stock | 2,500 | $16.00 | $40,000.00 |
DisclosureSEC source: 0001593968-21-002217 · primary_01.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2021 Filed Sep 1, 2021 20:28 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionOption (right to buy) · Derivative | 2,500 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001593968-21-002050 · primary_01.xml · derivative · entry 3 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 2,500 shares Expires 2029-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2021 Filed Sep 1, 2021 20:28 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 2,500 | $117.82 | $294,550.00 |
DisclosureSEC source: 0001593968-21-002050 · primary_01.xml · nonDerivative · entry 2 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2021. Read SEC document |
| September 01, 2021 Filed Sep 1, 2021 20:28 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionCommon Stock | 2,500 | $16.00 | $40,000.00 |
DisclosureSEC source: 0001593968-21-002050 · primary_01.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 13, 2021 Filed Aug 16, 2021 21:29 UTC | Immunovant, Inc. IMVT · Entity 3632 | PurchaseCommon Stock | 5,000 | $7.98 | $39,900.00 |
DisclosureSEC source: 0001764013-21-000088 · wf-form4_162914934479727.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Purchased through Trust Owned by Atul Pande and his Spouse Disclosed balance after: 45,200 Read SEC document |
| August 02, 2021 Filed Aug 2, 2021 20:49 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionOption (right to buy) · Derivative | 2,500 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001593968-21-001919 · primary_01.xml · derivative · entry 3 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 2,500 shares Expires 2029-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 02, 2021 Filed Aug 2, 2021 20:49 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 2,500 | $114.17 | $285,425.00 |
DisclosureSEC source: 0001593968-21-001919 · primary_01.xml · nonDerivative · entry 2 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 02, 2021 Filed Aug 2, 2021 20:49 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionCommon Stock | 2,500 | $16.00 | $40,000.00 |
DisclosureSEC source: 0001593968-21-001919 · primary_01.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2021 Filed Jul 1, 2021 20:19 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionOption (right to buy) · Derivative | 2,500 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001593968-21-001740 · primary_01.xml · derivative · entry 3 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 2,500 shares Expires 2029-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2021 Filed Jul 1, 2021 20:19 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 2,500 | $112.66 | $281,650.00 |
DisclosureSEC source: 0001593968-21-001740 · primary_01.xml · nonDerivative · entry 2 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 01, 2021 Filed Jul 1, 2021 20:19 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionCommon Stock | 2,500 | $16.00 | $40,000.00 |
DisclosureSEC source: 0001593968-21-001740 · primary_01.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 16, 2021 Filed Jun 23, 2021 20:35 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | GrantOption (right to buy) · Derivative | 8,500 | $0.00 Strike: $128.01 | $0.00 |
DisclosureSEC source: 0001593968-21-001685 · primary_01.xml · derivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2031-06-15 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 16, 2022, and (ii) the 2022 annual meeting of the Issuer's stockholders. Read SEC document |
| June 01, 2021 Filed Jun 1, 2021 20:45 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionOption (right to buy) · Derivative | 2,500 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001593968-21-001490 · primary_01.xml · derivative · entry 3 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 2,500 shares Expires 2029-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2021 Filed Jun 1, 2021 20:45 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 2,500 | $111.44 | $278,600.00 |
DisclosureSEC source: 0001593968-21-001490 · primary_01.xml · nonDerivative · entry 2 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 01, 2021 Filed Jun 1, 2021 20:45 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionCommon Stock | 2,500 | $16.00 | $40,000.00 |
DisclosureSEC source: 0001593968-21-001490 · primary_01.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2021 Filed May 3, 2021 21:10 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionOption (right to buy) · Derivative | 2,500 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001593968-21-001217 · primary_01.xml · derivative · entry 6 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 2,500 shares Expires 2029-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2021 Filed May 3, 2021 21:10 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 2,500 | $110.61 | $276,525.00 |
DisclosureSEC source: 0001593968-21-001217 · primary_01.xml · nonDerivative · entry 4 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 03, 2021 Filed May 3, 2021 21:10 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionCommon Stock | 2,500 | $16.00 | $40,000.00 |
DisclosureSEC source: 0001593968-21-001217 · primary_01.xml · nonDerivative · entry 3 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 20:55 UTC | Sio Gene Therapies Inc. SIOX · Entity 130622 | GrantStock Option (Right to Buy) · Derivative | 42,000 | $0.00 Strike: $2.47 | $0.00 |
DisclosureSEC source: 0001636050-21-000048 · wf-form4_161886571482336.xml · derivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2031-04-14 F1 · derivative.exercise_date: 100% of this option will vest on April 15, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested shares of common stock. All shares of common stock underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan. Read SEC document |
| April 01, 2021 Filed May 3, 2021 21:10 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionOption (right to buy) · Derivative | 2,500 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001593968-21-001217 · primary_01.xml · derivative · entry 5 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 2,500 shares Expires 2029-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2021 Filed May 3, 2021 21:10 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 2,500 | $120.01 | $300,025.00 |
DisclosureSEC source: 0001593968-21-001217 · primary_01.xml · nonDerivative · entry 2 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 01, 2021 Filed May 3, 2021 21:10 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionCommon Stock | 2,500 | $16.00 | $40,000.00 |
DisclosureSEC source: 0001593968-21-001217 · primary_01.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 19, 2021 Filed Mar 23, 2021 12:53 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 23,300 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001764013-21-000043 · wf-form4_161650399568493.xml · derivative · entry 2 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,300 Underlying: Common Stock · 23,300 shares Expires 2031-03-19 F2 · derivative.exercise_date: The shares underlying the options vest one year after the date of grant on March 19, 2022, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| March 19, 2021 Filed Mar 23, 2021 12:53 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 15,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-21-000043 · wf-form4_161650399568493.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,200 F1 · shares: Represents the number of shares underlying restricted stock unit awards ("RSUs") granted to the Reporting Person pursuant to a non-employee director grant. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in their entirety one year after the date of grant on March 19, 2022, subject to the Reporting Person's continued service to the Issuer as of such date; provided that the Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:19 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionOption (right to buy) · Derivative | 2,500 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001593968-21-000765 · primary_01.xml · derivative · entry 3 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 2,500 shares Expires 2029-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:19 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 2,500 | $125.43 | $313,575.00 |
DisclosureSEC source: 0001593968-21-000765 · primary_01.xml · nonDerivative · entry 2 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:19 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionCommon Stock | 2,500 | $16.00 | $40,000.00 |
DisclosureSEC source: 0001593968-21-000765 · primary_01.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2021 Filed Feb 1, 2021 21:23 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionOption (right to buy) · Derivative | 2,500 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001593968-21-000271 · primary_01.xml · derivative · entry 3 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 2,500 shares Expires 2029-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2021 Filed Feb 1, 2021 21:23 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 2,500 | $100.00 | $250,000.00 |
DisclosureSEC source: 0001593968-21-000271 · primary_01.xml · nonDerivative · entry 2 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 01, 2021 Filed Feb 1, 2021 21:23 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionCommon Stock | 2,500 | $16.00 | $40,000.00 |
DisclosureSEC source: 0001593968-21-000271 · primary_01.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2020 Filed Dec 14, 2020 22:10 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionOption (right to buy) · Derivative | 5,714 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001593968-20-002354 · primary_01.xml · derivative · entry 3 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,714 shares Expires 2026-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2020 Filed Dec 14, 2020 22:10 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 5,714 | $92.64 | $529,344.96 |
DisclosureSEC source: 0001593968-20-002354 · primary_01.xml · nonDerivative · entry 2 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 14, 2020 Filed Dec 14, 2020 22:10 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionCommon Stock | 5,714 | $2.92 | $16,684.88 |
DisclosureSEC source: 0001593968-20-002354 · primary_01.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,714 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 24, 2020 Filed Nov 26, 2020 02:07 UTC | Sio Gene Therapies Inc. SIOX · Entity 130622 | PurchaseCommon Stock | 10,000 | $2.34 | $23,399.00 |
DisclosureSEC source: 0001636050-20-000105 · wf-form4_160635640441285.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Atul C. Pande and Patricia A Pande TR DTD 08/24/2017 Disclosed balance after: 33,370 F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.33 to $2.34 per share, inclusive. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchase at each separate price within the range set forth in this footnote. Read SEC document |
| November 12, 2020 Filed Nov 12, 2020 21:23 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionOption (right to buy) · Derivative | 5,000 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001593968-20-002188 · primary_01.xml · derivative · entry 3 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,714 Underlying: Common Stock · 5,000 shares Expires 2026-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2020 Filed Nov 12, 2020 21:23 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 5,000 | $96.84 | $484,200.00 |
DisclosureSEC source: 0001593968-20-002188 · primary_01.xml · nonDerivative · entry 2 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 12, 2020 Filed Nov 12, 2020 21:23 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionCommon Stock | 5,000 | $2.92 | $14,600.00 |
DisclosureSEC source: 0001593968-20-002188 · primary_01.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2020 Filed Nov 3, 2020 21:44 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionOption (right to buy) · Derivative | 5,000 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001593968-20-002123 · primary_01.xml · derivative · entry 3 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,714 Underlying: Common Stock · 5,000 shares Expires 2026-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2020 Filed Nov 3, 2020 21:44 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 5,000 | $85.00 | $425,000.00 |
DisclosureSEC source: 0001593968-20-002123 · primary_01.xml · nonDerivative · entry 2 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 03, 2020 Filed Nov 3, 2020 21:44 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionCommon Stock | 5,000 | $2.92 | $14,600.00 |
DisclosureSEC source: 0001593968-20-002123 · primary_01.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 20:09 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionOption (right to buy) · Derivative | 5,000 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001593968-20-001897 · primary_01.xml · derivative · entry 3 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,714 Underlying: Common Stock · 5,000 shares Expires 2026-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 20:09 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 5,000 | $85.00 | $425,000.00 |
DisclosureSEC source: 0001593968-20-001897 · primary_01.xml · nonDerivative · entry 2 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 20:09 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionCommon Stock | 5,000 | $2.92 | $14,600.00 |
DisclosureSEC source: 0001593968-20-001897 · primary_01.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 20:19 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionOption (right to buy) · Derivative | 5,000 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001593968-20-001752 · primary_01.xml · derivative · entry 3 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,714 Underlying: Common Stock · 5,000 shares Expires 2026-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 20:19 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 5,000 | $85.00 | $425,000.00 |
DisclosureSEC source: 0001593968-20-001752 · primary_01.xml · nonDerivative · entry 2 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 20:19 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionCommon Stock | 5,000 | $2.92 | $14,600.00 |
DisclosureSEC source: 0001593968-20-001752 · primary_01.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.